The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characterization of the genetics of mucosal melanoma in patients treated with immunotherapy.
 
Elizabeth Iannotti Buchbinder
Employment - Biodesix (I); Sanofi (I); Smith & Nephew (I)
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals; Lilly; Merck; Novartis
 
Jason L. Weirather
No Relationships to Disclose
 
Michael P. Manos
No Relationships to Disclose
 
Ryan C. Brennick
No Relationships to Disclose
 
Patrick Alexander Ott
Consulting or Advisory Role - Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Genentech; Merck; Neon Therapeutics; Novartis; Pfizer
Research Funding - ARMO BioSciences (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Merck (Inst)
 
Rizwan Haq
Honoraria - Various healthcare surveys
Consulting or Advisory Role - Tango Therapeutics
Research Funding - Bristol-Myers Squibb; Novartis
Patents, Royalties, Other Intellectual Property - Patents issued: Mass General Hospital, co-inventor (2014) Patents pending: Dana-Farber Cancer Institute, co-inventor
 
Benjamin Izar
No Relationships to Disclose
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Stock and Other Ownership Interests - Apricity Health
Consulting or Advisory Role - Aduro Biotech; Amgen; Bayer; Bristol-Myers Squibb; Celldex; EMD Serono; Genentech/Roche; Incyte; Incyte; Incyte; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi; Verastem
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche